![]() ![]() (now Garnet Biotherapeutics), and a mentor to many in the life-sciences industry. (now Jannsen Biotech, Inc.) and Neuronyx, Inc. Schoemaker, Ph.D., a founder of Centocor, Inc. The Leadership Award recognizes the late Hubert J.P. He is also a member of the Board of Directors of the University City Science Center and Tela Bio, Inc. Previously, he served at the Centocor Diagnostics unit of Centocor, Inc., and at Johnson & Johnson. During his leadership of Fujirebio Diagnostics, the company became the worldwide leader in cancer-diagnostics. Touhey became Executive Chairman of Invisible Sentinel in 2013, following his appointment to the Board of Directors the previous year. He positively influences the people around him, and they are better for it." "He combines enthusiasm for innovation with the leadership skills required to turn bright ideas into marketed products. "We at Invisible Sentinel understand why Paul has earned enormous respect from everyone who has had the privilege to work with him," said Nicholas Siciliano, Chief Executive Officer at Invisible Sentinel. Touhey is a previous winner of Pennsylvania BIO's CEO of the Year Award. The leadership award recognizes an outstanding leader in the life-sciences community who exemplifies the spirit of innovation. Touhey, formerly President and Chief Executive Officer of Fujirebio Diagnostics, Inc., will be honored at Pennsylvania BIO's Annual Dinner and Awards Celebration March 12 at the Pennsylvania Convention Center in Philadelphia. ![]() Stem cell therapy, so long a therapeutic chimera, now seems ripe for commercial exploitation.PHILADELPHIA, PA-(Marketwired - Mar 10, 2014) - Invisible Sentinel Inc., a life-sciences company that develops rapid diagnostics for the food and beverage industries, congratulates Paul Touhey, the company's Executive Chairman, on his receipt of Pennsylvania BIO's Hubert J.P. But these and other hurdles shouldn't obscure the growing opportunity. Nonetheless, the stem cell industry has remained a start-up's trade, and it's easy to see why: large-company experiences in the area have not, for the most part, been happy ones, as companies face the issues of installing unpharma-like infrastructures to deliver personalized therapy, as well as ethical concerns, which must be given appropriate consideration. The transplant replacement business-regenerative medicine-has caught the public's attention. ![]() Meanwhile, researchers have transformed fully committed adult stem cells into cells of different lineages, raising the possibility that alternatives to ESCs for tissue replacement or repair exist. But recent developments have stirred the competitive pot: a number of companies have created methods for growing enough adult stem cells to provide them to significant numbers of patients. Geron, the only player in this group to have benefited from the last nine months of biotech stock mania, holds a key competitive advantage: its ability to use embryonic stem cells (ESCs) to create, theoretically, nearly infinite quantities of any cell in the body. For the most part, companies have had to propose autologous transplantation strategies or, at best, transplants from one donor for just a few patients-an economically difficult-to-justify business. Beyond the lack of clinical conformation, stem cell transplantation therapy has been held back by the inability to culture large quantities of cells-as with whole organ transplants, there simply isn't enough tissue to go around. Stem cell trials are finally in progress, allowing investors and corporate partners to finally see just how effective this multi-billion-dollar opportunity to replace many highly problematic organ transplants, and dramatically expand the procedures into new areas, can be. Physicians, patients, and companies can now see the stem cell transplant business taking shape. ![]()
0 Comments
Leave a Reply. |